VISINE L.R.
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VISINE L.R. (VISINE L.R.).
Selective alpha-1 adrenergic receptor agonist; constricts conjunctival blood vessels via stimulation of alpha-1 adrenoreceptors in the ophthalmic artery, reducing redness and edema.
| Metabolism | Metabolized primarily by hepatic monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT); systemic absorption is minimal. |
| Excretion | Primarily renal excretion of unchanged drug and metabolites; ~90% of an oral dose is excreted in urine within 24 hours; biliary/fecal excretion accounts for <5%. |
| Half-life | Terminal elimination half-life is 2.1 ± 0.2 hours for the racemic mixture; clinical context: dosing intervals typically every 4-6 hours. |
| Protein binding | <5% bound to plasma proteins (albumin). |
| Volume of Distribution | Vd approximately 0.2 L/kg; indicates limited extravascular distribution. |
| Bioavailability | Ocular topical: systemic bioavailability is very low (<1%) due to local vasoconstriction and minimal absorption; oral bioavailability ~10% due to first-pass metabolism. |
| Onset of Action | Ocular topical: vasoconstriction occurs within minutes; peak effect at 15-30 minutes. |
| Duration of Action | Duration of vasoconstriction is 4-6 hours following topical ocular administration; clinical note: prolonged use may lead to rebound hyperemia. |
1 to 2 drops in the affected eye(s) every 8 to 12 hours, not to exceed 2 drops per eye every 8 hours. Ophthalmic solution 0.05%.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required for GFR changes. Excretion of oxymetazoline is renal, but systemic absorption is minimal. |
| Liver impairment | No specific dose adjustment for Child-Pugh class A, B, or C. Use with caution in severe hepatic impairment due to potential for systemic effects. |
| Pediatric use | Children 6 years and older: 1 drop in affected eye(s) every 8 hours as needed. Not recommended for children under 6 years due to risk of systemic toxicity. |
| Geriatric use | Use same as adult dosing. Monitor for increased systemic absorption due to age-related ocular surface changes and potential for cardiovascular effects (e.g., hypertension, tachycardia). |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VISINE L.R. (VISINE L.R.).
| Breastfeeding | No data on excretion in human milk. Systemic absorption after ocular administration is minimal; however, it is not known if oxymetazoline is excreted in breast milk. Caution should be exercised. M/P ratio not determined. |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Based on limited human data, no increased risk of major birth defects or miscarriage has been observed with ophthalmic oxymetazoline. However, systemic absorption is minimal, and the risk is considered low. Use only if clearly needed. |
■ FDA Black Box Warning
None
| Serious Effects |
Narrow-angle glaucoma, hypersensitivity to oxymetazoline or any component of the formulation, patients receiving monoamine oxidase inhibitors (MAOIs) or tricyclic antidepressants (TCAs) due to risk of hypertensive crisis.
| Precautions | Avoid use in patients with narrow-angle glaucoma or known hypersensitivity to oxymetazoline; discontinue if ocular pain, vision changes, or headache occur; prolonged use may cause rebound hyperemia; use caution in patients with cardiovascular disease (e.g., hypertension, arrhythmias) or hyperthyroidism; not for use in children under 6 years. |
Loading safety data…
| Fetal Monitoring | No specific monitoring required beyond routine prenatal care. Monitor for any ocular adverse effects or systemic effects (e.g., hypertension, tachycardia) if used excessively. |
| Fertility Effects | No studies on fertility effects. No known impact on fertility or reproduction. |